5 of Last Week's Biggest Losers

There's never a shortage of losers in the stock market. Let's take a closer look at five of this past week's biggest sinkers.

Company

Feb. 15

Weekly Loss

Cliffs Natural Resources (NYSE: CLF  )

$28.85

21%

Level 3 Communications  (NYSE: LVLT  )

$20.81

15%

Heckmann  (NYSE: NES  )

$3.84

12%

Dendreon  (NASDAQOTH: DNDNQ  )

$6.07

12%

3D Systems  (NYSE: DDD  )

$59.53

11%

Source: Barron's.

Cliffs Natural Resources found several ways to disappoint investors. The iron ore producer posted a huge quarterly deficit, following that up with news that it will slash its dividend from $0.625 to $0.15 a share and complete a secondary offering to raise $1 billion.

Level 3 Communications was taken down a few levels after falling short on the bottom line. The provider of communications services to enterprise, government, and carrier customers served up a larger loss than analysts were forecasting. This shouldn't really come as a surprise to investors. This is the same thing that happened every single quarter at Level 3 last year.

Heckmann slipped after Wedbush analyst David Rose downgraded the provider of fracking wastewater solution. Rose is slapping the stock with an "underperform" rating and slashing his price target all the way down to $2.50.

Denderon may have a promising vaccine to tackle prostate cancer, but that's not enough for at least one analyst. Maxim Group downgraded shares of Dendreon, tagging the stock with a grim "sell" rating and a price target of $4.

Finally we have 3D Systems tumbling after a bearish report on the poster child of 3-D printing. Noted worrywart Citron Research made 3D Systems its latest target, tagging it as a "bubble stock."

Ready for a bounce
If you owned some of these losers, how about following the smart money into winners?

The retail space is in the midst of the biggest paradigm shift since mail order took off at the turn of last century. Only the most forward-looking and capable companies will survive, and they'll handsomely reward investors who understand the landscape. You can read about the 3 Companies Ready to Rule Retail in The Motley Fool's special report. Uncovering these top picks is free today; just click here to read more.


Read/Post Comments (1) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On February 17, 2013, at 7:06 PM, lebronz wrote:

    Dendreon a loser Rick; Really?

    Besides looking at the WEEKLY stock price trends (which for dndn is due to massive shorting of millions of shares), do you or the Motley ownership really know how to value a biotech longterm? Do you know that DNDN owns the the first ever, patented, FDA approved, therapeutic cancer vaccine that harnesses a dying mans immune system to prolong his life from mCRPC?

    You should've sent this weak article that includes DNDN to Blackrock Inc, Deerfield, and Vanguard who recently took gargantuan passive stakes and now own in aggregate about 26 million dndn shares all together.

    See all 3 13G's here: http://investor.dendreon.com/sec.cfm

    And remember, we can see these large purchases by major tutes because they were >5%. Imagine what purchases we can't see happening this quarter until May 15!

    Institutional accumulation has already gone from 58% in Q2/2012 to 63% in Q4/2012.

    With Blackrock Inc's recent 8 million share purchase and Deerfields increase to a 5.77% stake in Q1/2013, that puts tute holdings around 70%.

    Does the Motley owner or any Motley writer their track institutional accumulation of novel biotechs while the stock is being shorted to death? http://www.nasdaq.com/symbol/dndn/short-interest

    Can you, the Motley owner or David Williamson recognize an invisble BEAR RAID on a biotech via massively shorting millions of shares over the last 18 months, while major institutions are accumulating?

    I have confidence that you will after you witness what happens to dendreon over the next 3 years prior to Jan 2016 when the convertible is due.

    Oh, while you're Motley owner and David Williamson want you to focus on quarterly sales, have you, as the unique individual you are, looked at YOY Provenge sales.

    Obviously you haven't, but maybe you can see a trend?

    2010- $46M

    2011- $216M

    2012- $322M

    2013

    2014

    2015

    2016: $600M Convertible note due (JP Morgan will convert and get their 42.3 million shares once dndn is above $51 and become dndn's largest shareholder (and after institutional shorts massively and strategically cover from CEO Johnson providing yearly guidance again or some other binary event; and after their institutional partners own 90% of the company).

    http://www.streetinsider.com/holdings.php?q=DNDN

    2017

    2018

    2019

    2020

    2021

    I wrote out the years because dndn has 12 years market exclusivity for Provenge under Obamacare. Because of this, institutional shorts will continue massively shorting this stock while they steadily and stealthily accumulate and own greater than 90% of dndn.

    You also forgot to mention that short interest has been trending upward from 14 million back in August 2011 (when M Gold pulled guidance and was the trigger for the massive short bear raid attack) to 50 million TODAY.

    50 million is the highest its ever been. This is the invisible bear raid that drove the price down from $17 to where it is today.

    Ever wonder why CEO Johnson is mum about this massive invisible bear raid short attack? Ever wonder why the HLF CEO chooses to defend his company against their hedgefund short attack?

    The monthly flooding of nearly 2 million shares per month since last February has driven the price down from $17....while major institutions continue accumulating.

    You may ask why would hedgie shorts want to drive out retail over the last 16 months. Well, this is a TIME game and 16 months is nothing in the 12 market exclusivity timeline that Provenge will enjoy (until April 2022; no threat from biosimilar).

    But why you ask...> ? The answer is the size of the U.S. mCRPC market.

    30,000 men are newly diagnosed each year w/ mCRPC

    60,000 men are living with mCRPC

    dndn is only treating 3440 per year (2012) or 860 per quarter.

    Once dndn treats 1076 per quarter (or 4304 annually) that is their breakeven ($100M) and it's still BARELY A DENT in the U.S. mCRPC market.

    Oh, and any wallstreet phobia theory of competition threatening Provenge sales is incredibly weak. Dying patients and ethical doctors will sequence the available therapies to prolong the dying man's Quality of Life and length of his life to the MAXIMUM! Someday your Motley owner will get that thru his thick skull.....

    Oh, and tell David Williamson that no one wants to spend money to buy a "premium research report on DNDN" when it should just be one word long....................and that's BUY! As a young man David should be thinking how he can help the retail investor versus wallstreet institutions...otherwise he'll end up with no heartstrings to pull whatsoever like Adam F from the Street. Tell David to take the "Tombstone Test" now before he gets older. The Motley owner may already be captured, but its never too late to change.

    Tell everyone about DNDN now Rick before major greedy institutions own 90% of the 154 million outstanding shares of DNDN.

    DNDN should be a retailers stock, not owned all by wallstreet!

    Leb

    ps: Expect institutional shorts to short a positive EU CHMP opinion this Friday, 22nd so they can continue their strategic share accumulation strategy over TIME (because dndn won't do another secondary offering).

    And expect media articles (eg: Motley) will follow about how this positive EU CHMP approval is actually a negative in some way or another...and institutional shorts will support any media negative slant of course by shorting millions as has been the pattern for the last 18 months.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2260368, ~/Articles/ArticleHandler.aspx, 12/18/2014 11:00:23 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement